🎁 Black Friday: up to 50% off of annual plans
TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
63.34
-1.54 (-2.37%)
At close: Nov 20, 2026, 4:00 PM EST
63.65
+0.31 (0.49%)
After-hours: Nov 20, 2026, 7:56 PM EST

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $8.87 billion. The enterprise value is $9.12 billion.

Market Cap8.87B
Enterprise Value 9.12B

Important Dates

The last earnings date was Monday, November 9, 2026, before market open.

Earnings Date Nov 9, 2026
Ex-Dividend Date n/a

Share Statistics

TG Therapeutics has 140.10 million shares outstanding. The number of shares has decreased by -2.16% in one year.

Current Share Class 140.10M
Shares Outstanding 140.10M
Shares Change (YoY) -2.16%
Shares Change (QoQ) -0.86%
Owned by Insiders (%) 4.68%
Owned by Institutions (%) 88.18%
Float 133.50M

Valuation Ratios

The trailing PE ratio is 95.92 and the forward PE ratio is 23.44. TG Therapeutics's PEG ratio is 1.53.

PE Ratio 95.92
Forward PE 23.44
PS Ratio 9.88
Forward PS 6.97
PB Ratio 15.51
P/TBV Ratio 15.51
P/FCF Ratio 103.71
P/OCF Ratio 102.88
PEG Ratio 1.53
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 47.26, with an EV/FCF ratio of 106.63.

EV / Earnings 86.02
EV / Sales 10.16
EV / EBITDA 47.26
EV / EBIT 47.31
EV / FCF 106.63

Financial Position

The company has a current ratio of 4.50, with a Debt / Equity ratio of 1.32.

Current Ratio 4.50
Quick Ratio 3.54
Debt / Equity 1.32
Debt / EBITDA 3.87
Debt / FCF 8.82
Interest Coverage 4.14

Financial Efficiency

Return on equity (ROE) is 17.99% and return on invested capital (ROIC) is 17.63%.

Return on Equity (ROE) 17.99%
Return on Assets (ROA) 8.10%
Return on Invested Capital (ROIC) 17.63%
Return on Capital Employed (ROCE) 14.48%
Weighted Average Cost of Capital (WACC) 13.43%
Revenue Per Employee $2.25M
Profits Per Employee $265,810
Employee Count399
Asset Turnover 0.69
Inventory Turnover 0.91

Taxes

In the past 12 months, TG Therapeutics has paid $43.49 million in taxes.

Income Tax 43.49M
Effective Tax Rate 29.08%

Stock Price Statistics

The stock price has increased by +108.84% in the last 52 weeks. The beta is 1.81, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 1.81
52-Week Price Change +108.84%
50-Day Moving Average 57.58
200-Day Moving Average 46.25
Relative Strength Index (RSI) 57.18
Average Volume (20 Days) 2,197,659

Short Selling Information

The latest short interest is 28.77 million, so 20.53% of the outstanding shares have been sold short.

Short Interest 28.77M
Short Previous Month 29.59M
Short % of Shares Out 20.53%
Short % of Float 21.55%
Short Ratio (days to cover) 18.16

Income Statement

In the last 12 months, TG Therapeutics had revenue of $897.76 million and earned $106.06 million in profits. Earnings per share was $0.66.

Revenue897.76M
Gross Profit 742.84M
Operating Income 192.86M
Pretax Income 149.55M
Net Income 106.06M
EBITDA 193.04M
EBIT 192.86M
Earnings Per Share (EPS) $0.66
Full Income Statement

Balance Sheet

The company has $504.67 million in cash and $754.37 million in debt, with a net cash position of -$249.70 million or -$1.78 per share.

Cash & Cash Equivalents 504.67M
Total Debt 754.37M
Net Cash -249.70M
Net Cash Per Share -$1.78
Equity (Book Value) 572.13M
Book Value Per Share 4.08
Working Capital 910.92M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $86.26 million and capital expenditures -$693,000, giving a free cash flow of $85.56 million.

Operating Cash Flow 86.26M
Capital Expenditures -693,000
Depreciation & Amortization 179,000
Net Borrowing 492.66M
Free Cash Flow 85.56M
FCF Per Share $0.61
Full Cash Flow Statement

Margins

Gross margin is 82.74%, with operating and profit margins of 21.48% and 11.81%.

Gross Margin 82.74%
Operating Margin 21.48%
Pretax Margin 16.66%
Profit Margin 11.81%
EBITDA Margin 21.50%
EBIT Margin 21.48%
FCF Margin 9.53%

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 2.16%
Shareholder Yield 2.16%
Earnings Yield 1.04%
FCF Yield 0.96%

Analyst Forecast

The average price target for TG Therapeutics is $69.43, which is 9.62% higher than the current price. The consensus rating is "Buy".

Price Target $69.43
Price Target Difference 9.62%
Analyst Consensus Buy
Analyst Count 8
Revenue Growth Forecast (3Y) 39.31%
EPS Growth Forecast (3Y) 9.93%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.

Last Split Date Apr 30, 2012
Split Type Reverse
Split Ratio 1:56.25

Scores

TG Therapeutics has an Altman Z-Score of 4.12 and a Piotroski F-Score of 5.

Altman Z-Score 4.12
Piotroski F-Score 5